Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Clin Cancer Res. 2018 Oct 23;25(4):1248–1260. doi: 10.1158/1078-0432.CCR-18-1640

Figure 5: MEK inhibition suppresses MET through transcription and protein level.

Figure 5:

A. Lysate from stably transfected 3T3-METex14-KRAS WT, G12D, or G12S cells were collected at the indicated time points after addition of cycloheximide (CHX, 100 μg/mL) and subjected to immunoblotting. B. The amount of MET protein was quantified and is shown relative to the amount of MET expressed in absence of CHX. Data are representative of three independent experiments (mean ± SE).*p<0.05, compared to 3T3-METex14-KRAS WT cells. C. MET mRNA expression level of was determined by RT-qPCR in KRAS knockdown LUAD12C cells after selection. Each condition was assayed in triplicate determinations (mean ± SD). D. LUAD12C cells were treated with trametinib (25 nM) for the indicated time and mRNA expression levels of MET were analyzed by RT-qPCR. Experiments were conducted in triplicate and error bars represent mean ± SD. E. LUAD12C cells were treated with trametinib (25 nM) for the indicated time. Lysates were subjected to immunoblotting.